Skip to main content
Signal8

COLLEGIUM PHARMACEUTICAL, INC (COLL)

Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.

Sector: Pharmaceutical Preparations

Industry: Drug Manufacturers - Specialty & Generic

Collegium Pharmaceutical, Inc. logo

Collegium Pharmaceutical, Inc.

NASDAQ:COLLHealthcare
-0.96%$23.80
AH$23.80+0.00%vs close
Mkt Cap$774.82M
Float29.55M
O/S32.56M
Vol
$ Vol
RVOL
Inst Own-
SI18.2%
Earnings
Dilution
Pipeline1 lead-sponsored trial·0 active1 completed(3 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
  • Phase 3
    Completed

    Oxycodone DETERx™ Versus Placebo in Chronic Low Back Pain (CLBP)

    Oxycodone DETERx, Placebo

    Chronic Low Back Pain

    Enrollment
    740
    Start
    Aug 2012
    Primary Completion
    Jun 2014
    Completion
    Jul 2014
    NCT01685684